Cytonics Corporation has initiated enrollment for its Phase 1 clinical trial of CYT-108, a novel variant of alpha-2-macroglobulin (A2M) aimed at addressing cartilage degradation in osteoarthritis (OA). This engineered protein targets proteases responsible for cartilage breakdown in arthritic joints, offering enhanced inhibitory activity against major protease classes while retaining broad-spectrum anti-protease capabilities.

Joey Bose, President & CEO of Cytonics, emphasized the significance of this milestone: "Our Phase 1 trial represents the culmination of six years of intensive research and development. Overcoming significant technical hurdles in developing CYT-108, including its complex folding structure and large size (720kD), was a remarkable scientific achievement led by Lewis Hanna, PhD, our Chief Scientific Officer." Preclinical data has shown promising indications of CYT-108's protective effects on cartilage and other joint components implicated in OA progression.

The study aims to assess CYT-108's safety and effectiveness in knee OA patients through intra-articular administration at two intervals, with monitoring over 90 days post-dosing. Evaluations will focus on joint pain, stiffness, mobility, pharmacokinetics, and overall tolerability.

CYT-108 utilizes its engineered "bait" region to increase affinity for targeted proteases crucial to OA development, distinguishing it from traditional small-molecule inhibitors. Cytonics is confident in CYT-108's potential, bolstered by the clinical and commercial success of its first-generation therapy, the Autologous Protease Inhibitor Concentrate (APIC) system, which has treated over 8,000 patients since FDA clearance in 2015.

In summary, CYT-108 represents a promising candidate in disease-modifying OA treatments, leveraging the established safety and efficacy of APIC's A2M enrichment technology.

 

Source: prnewswire.com

Report Abuse